Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 745239, 5 pages
http://dx.doi.org/10.1155/2013/745239
Review Article

Targeting the B-Cell Pathway in Lupus Nephritis: Current Evidence and Future Perspectives

1Department of Nephrology, Papageorgiou Hospital, 56403 Thessaloniki, Greece
22nd Propedeutic Department of Internal Medicine, Hippokration General Hospital, 54642 Thessaloniki, Greece

Received 10 August 2013; Accepted 3 September 2013

Academic Editors: L. J. Catoggio and R. Sanmartí

Copyright © 2013 Panagiotis Pateinakis and Athina Pyrpasopoulou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. S. Cameron, “Lupus nephritis,” Journal of the American Society of Nephrology, vol. 10, no. 2, pp. 413–424, 1999. View at Google Scholar · View at Scopus
  2. M. Patel, A. M. Clarke, I. N. Bruce, and D. P. M. Symmons, “The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient,” Arthritis and Rheumatism, vol. 54, no. 9, pp. 2963–2969, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. Yong, M. C. Killingsworth, and K. Lai, “Renal biopsy pathology in a cohort of patients from southwest Sydney with clinically diagnosed systemic lupus erythematosus,” International Journal of Nephrology and Renovascular Disease, vol. 6, pp. 15–26, 2013. View at Publisher · View at Google Scholar
  4. T. C. Tan, H. Fang, L. S. Magder, and M. A. Petri, “Differences between male and female systemic lupus erythematosus in a multiethnic population,” Journal of Rheumatology, vol. 39, no. 4, pp. 759–769, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. L. Resende, S. M. Titan, R. T. Barros, and V. Woronik, “Worse renal outcome of lupus nephritis in male patients: a case-control study,” Lupus, vol. 20, no. 6, pp. 561–567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Ferraccioli and E. Gremese, “Class IV-G and IV-S lupus nephritis, interstitial infiltrates and prognosis: state of the art and unmet medical needs,” Giornale Italiano di Nefrologia, vol. 29, no. 6, pp. 655–660, 2012. View at Google Scholar
  7. J. Hogan and G. B. Appel, “Update on the treatment of lupus nephritis,” Current Opinion in Nephrology and Hypertension, vol. 22, no. 2, pp. 224–230, 2013. View at Google Scholar
  8. R. S. Flanc, M. A. Roberts, G. F. Strippoli, S. J. Chadban, P. G. Kerr, and R. C. Atkins, “Treatment for lupus nephritis,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD002922, 2004. View at Google Scholar · View at Scopus
  9. L. Lightstone, “Minimising steroids in lupus nephritis—will B cell depletion pave the way?” Lupus, vol. 22, no. 4, pp. 390–399, 2013. View at Google Scholar
  10. D. Y. Yap, M. K. Ma, M. M. Mok, C. S. Tang, and T. M. Chan, “Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis,” Rheumatology, vol. 52, no. 3, pp. 480–486, 2013. View at Google Scholar
  11. A. T. Borchers, N. Leibushor, S. M. Naguwa, G. S. Cheema, Y. Shoenfeld, and M. E. Gershwin, “Lupus nephritis: a critical review,” Autoimmunity Reviews, vol. 12, no. 2, pp. 174–194, 2012. View at Publisher · View at Google Scholar
  12. A. Rahman and D. A. Isenberg, “Systemic lupus erythematosus,” New England Journal of Medicine, vol. 358, no. 9, pp. 929–939, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Koffler, P. H. Schur, and H. G. Kunkel, “Immunological studies concerning the nephritis of systemic lupus erythematosus,” Journal of Experimental Medicine, vol. 126, no. 4, pp. 607–624, 1967. View at Google Scholar · View at Scopus
  14. D. S. Pisetsky, “Antinuclear antibodies in healthy people: the tip of autoimmunity's iceberg?” Arthritis Research and Therapy, vol. 13, no. 2, article 109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Yung and T. M. Chan, “Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown,” Clinical and Developmental Immunology, vol. 2012, Article ID 139365, 13 pages, 2012. View at Publisher · View at Google Scholar
  16. R. E. Voll, M. Herrmann, E. A. Roth, C. Stach, J. R. Kalden, and I. Girkontaite, “Immunosuppressive effects of apoptotic cells,” Nature, vol. 390, no. 6658, pp. 350–351, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. L. E. Muñoz, C. Janko, G. E. Grossmayer et al., “Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 60, no. 6, pp. 1733–1742, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Pisetsky, “Cell death in the pathogenesis of immune-mediated diseases: the role of HMGB1 and DAMP-PAMP complexes,” Swiss Medical Weekly, vol. 141, Article ID w13256, 2011. View at Google Scholar · View at Scopus
  19. D. S. Pisetsky and A. J. Ullal, “The blood nucleome in the pathogenesis of SLE,” Autoimmunity Reviews, vol. 10, no. 1, pp. 35–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Yung and T. M. Chan, “Anti-DNA antibodies in the pathogenesis of lupus nephritis—the emerging mechanisms,” Autoimmunity Reviews, vol. 7, no. 4, pp. 317–321, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Zhang, J. Yang, S. Jiang et al., “The lupus-derived anti-double-stranded DNA IgG contributes to myofibroblast-like phenotype in mesangial cells,” Journal of Clinical Immunology, vol. 32, no. 6, pp. 1270–1278, 2012. View at Google Scholar
  22. O. T. M. Chan, M. P. Madaio, and M. J. Shlomchik, “The central and multiple roles of B cells in lupus pathogenesis,” Immunological Reviews, vol. 169, pp. 107–121, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. J. H. Anolik, “B cell biology: implications for treatment of systemic lupus erythematosus,” Lupus, vol. 22, no. 4, pp. 342–349, 2013. View at Google Scholar
  24. S. Ahmed and J. H. Anolik, “B-cell biology and related therapies in systemic lupus erythematosus,” Rheumatic Disease Clinics of North America, vol. 36, no. 1, pp. 109–130, 2010. View at Publisher · View at Google Scholar
  25. V. Marian and J. H. Anolik, “Treatment targets in systemic lupus erythematosus: biology and clinical perspective,” Arthritis Research and Therapy, vol. 14, supplement 4, article S3, 2012. View at Google Scholar
  26. K. R. Kumar, L. Li, M. Yan et al., “Regulation of B cell tolerance by the lupus susceptibility gene Ly108,” Science, vol. 312, no. 5780, pp. 1665–1669, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Mackay, A. Stanevsky, T. Wang et al., “Selective dysregulation of the FcγIIB receptor on memory B cells in SLE,” Journal of Experimental Medicine, vol. 203, no. 9, pp. 2157–2164, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. Y.-H. Cheung, C. Loh, E. Pau, J. Kim, and J. Wither, “Insights into the genetic basis and immunopathogenesis of systemic lupus erythematosus from the study of mouse models,” Seminars in Immunology, vol. 21, no. 6, pp. 372–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Liu and A. Davidson, “BAFF and selection of autoreactive B cells,” Trends in Immunology, vol. 32, no. 8, pp. 388–394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Reddy, D. Jayne, D. Close, and D. Isenberg, “B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design,” Arthritis Research and Therapy, vol. 15, supplement 1, article S2, 2013. View at Publisher · View at Google Scholar
  31. J. T. Merrill, C. M. Neuwelt, D. J. Wallace et al., “Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial,” Arthritis and Rheumatism, vol. 62, no. 1, pp. 222–233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. B. H. Rovin, R. Furie, K. Latinis et al., “Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study,” Arthritis and Rheumatism, vol. 64, no. 4, pp. 1215–1226, 2012. View at Google Scholar
  33. “Lupus nephritis. Phase III ocrelizumab trial halted by infections,” Nature Reviews Rheumatology, vol. 9, no. 8, article 444, 2013.
  34. E. F. Mysler, A. J. Spindler, and R. Guzman, “Efficacy and safety of Ocrelizumab in active proliferative lupus nephritis: results from the randomized, double-blind phase III BELONG Study,” Arthritis and Rheumatism, 2013. View at Google Scholar
  35. T. Jónsdóttir, A. Zickert, B. Sundelin, E. W. Henriksson, R. F. van Vollenhoven, and I. Gunnarsson, “Long-term follow-up in lupus nephritis patients treated with rituximab—clinical and histopathological response,” Rheumatology, vol. 52, no. 5, pp. 847–855, 2013. View at Google Scholar
  36. C. Y. Sun, Y. Shen, X. W. Chen et al., “The Characteristics and Significance of Locally Infiltrating B Cells in Lupus Nephritis and Their Association with Local BAFF Expression,” International Journal of Rheumatology, vol. 2013, Article ID 954292, 9 pages, 2013. View at Publisher · View at Google Scholar
  37. S. Manzi, J. Sánchez-Guerrero, J. T. Merrill et al., “Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials,” Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1833–1838, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. L. M. Carter, D. A. Isenberg, and M. R. Ehrenstein, “Elevated serum B-cell activating factor (BAFF/BLyS) is associated with rising anti-dsDNA antibody levels and flare following B-cell depletion therapy in systemic lupus erythematosus,” Arthritis and Rheumatism, 2013. View at Google Scholar
  39. Z. Rosman, Y. Shoenfeld, and G. Zandman-Goddard, “Biologic therapy for autoimmune diseases: an update,” BMC Medicine, vol. 11, article 88, 2013. View at Publisher · View at Google Scholar
  40. D. J. Wallace, K. Kalunian, M. A. Petri et al., “Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study,” Annals of the Rheumatic Diseases, 2013. View at Google Scholar
  41. D. J. Wallace, C. Gordon, and V. Strand, “Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up,” Rheumatology, vol. 52, no. 7, pp. 1313–1322, 2013. View at Google Scholar
  42. R. J. Davies, S. R. Sangle, N. P. Jordan et al., “Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis,” Lupus, vol. 22, no. 6, pp. 574–582, 2013. View at Google Scholar
  43. S. Y. Bang, C. K. Lee, and Y. M. Kang, “Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus,” Autoimmune Disease, vol. 2012, Article ID 565039, 6 pages, 2012. View at Publisher · View at Google Scholar
  44. M. Weidenbusch, C. Römmele, A. Schröttle, and H. J. Anders, “Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis,” Nephrology Dialysis Transplantation, vol. 28, no. 1, pp. 106–111, 2013. View at Google Scholar
  45. L. Lightstone, “The landscape after LUNAR: rituximab's crater-filled path,” Arthritis and Rheumatism, vol. 64, no. 4, pp. 962–965, 2012. View at Google Scholar
  46. M. B. Condon, D. Ashby, R. J. Pepper et al., “Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids,” Annals of the Rheumatic Diseases, vol. 72, no. 8, pp. 1280–1286, 2013. View at Google Scholar